Characteristics of the study population at entry
| Patient characteristic . | n (%) . |
|---|---|
| Patients | 50 (100) |
| Sex | |
| Male | 43 (86) |
| Female | 7 (14) |
| WHO performance status | |
| 0 | 10 (20) |
| 1 | 27 (54) |
| 2 | 13 (26) |
| Risk group for HIV infection | |
| Intravenous drug use | 24 (48) |
| Homosexual male | 13 (26) |
| Heterosexual contact | 9 (18) |
| Unknown | 4 (8) |
| Previous AIDS-defining event (other than lymphoma) | 15 (30) |
| CD4+ count | |
| < 100 cells/mL | 11 (22) |
| < 200 cells/mL | 21 (42) |
| HIV viral load | |
| Undetectable | 39 (78) |
| Detectable | 11 (22) |
| HCV-positive | 22 (44) |
| Histology | |
| Non-Hodgkin | 31 (62) |
| Hodgkin | 19 (38) |
| Status of lymphoma | |
| First relapse | 22 (44) |
| Second relapse | 3 (6) |
| Refractory | 20 (40) |
| Partial remission | 5 (10) |
| Stage of lymphoma | |
| II | 7 (14) |
| III | 13 (26) |
| IV | 30 (60) |
| B symptoms | 20 (40) |
| Extranodal involvement | 31 (62) |
| Bone marrow involvement | 13 (26) |
| LDH greater than normal value | 17 (36) |
| Patient characteristic . | n (%) . |
|---|---|
| Patients | 50 (100) |
| Sex | |
| Male | 43 (86) |
| Female | 7 (14) |
| WHO performance status | |
| 0 | 10 (20) |
| 1 | 27 (54) |
| 2 | 13 (26) |
| Risk group for HIV infection | |
| Intravenous drug use | 24 (48) |
| Homosexual male | 13 (26) |
| Heterosexual contact | 9 (18) |
| Unknown | 4 (8) |
| Previous AIDS-defining event (other than lymphoma) | 15 (30) |
| CD4+ count | |
| < 100 cells/mL | 11 (22) |
| < 200 cells/mL | 21 (42) |
| HIV viral load | |
| Undetectable | 39 (78) |
| Detectable | 11 (22) |
| HCV-positive | 22 (44) |
| Histology | |
| Non-Hodgkin | 31 (62) |
| Hodgkin | 19 (38) |
| Status of lymphoma | |
| First relapse | 22 (44) |
| Second relapse | 3 (6) |
| Refractory | 20 (40) |
| Partial remission | 5 (10) |
| Stage of lymphoma | |
| II | 7 (14) |
| III | 13 (26) |
| IV | 30 (60) |
| B symptoms | 20 (40) |
| Extranodal involvement | 31 (62) |
| Bone marrow involvement | 13 (26) |
| LDH greater than normal value | 17 (36) |
WHO indicates World Health Organization; and HCV, hepatitis C virus.